Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is exploring adding ipatasertib to pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• ipatasertib (ipatasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING